Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy versus bevacizumab plus chemotherapy in PD-L1-negative advanced non-squamous NSCLC
ChiCTR2000032288Phase 3Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab, bevacizumab, pemetrexed, carboplatin and cisplatin in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Progression-free survival. Planned start May 2020; status: not yet recruiting.
02
Drugs
camrelizumabbevacizumabpemetrexedcarboplatincisplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2000032288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032288.